New England Journal of Medicine· 2022Q1

Empagliflozin in Patients with Chronic Kidney Disease

The EMPA-KIDNEY Collaborative Group

2,449citations
Q1SCImago
2022year

Short summary

Empagliflozin significantly reduced the risk of kidney disease progression or cardiovascular death by 28% (HR 0.72) compared to placebo in a broad range of chronic kidney disease (CKD) patients over a median of 2 years.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Endocrinology, Diabetes and Metabolism

Endocrinology, Diabetes and MetabolismMedicine